TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF

Telix Pharmaceuticals Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026

$10.74+0.05 (+0.47%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Aug 20, 2026	After market close	$477.00M	–	–

Company guidance

Outlook given with results on Aug 20, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
R&D	FY 2026	$230.00M to $270.00M	New
revenue guidance	FY 2026	$950.00M to $970.00M	New

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Telix Pharmaceuticals filed with the SEC

Sep 29, 2026, 8:19 PM ET
EX-99 to Form 6-K
EX-99 to Form 6-K
Sep 21, 2026, 8:55 AM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Sep 21, 2026, 8:55 AM ET
A radiopharmaceutical powerhouse with enhanced capabilities across the value chain Telix + ITM Telix Pharmaceuticals ASX: TLX | NASDAQ: TLX September 21, 2026
EX-99.2 to Form 6-K
Sep 14, 2026, 4:52 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Sep 1, 2026, 8:30 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Aug 31, 2026, 8:39 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Aug 19, 2026, 9:48 PM ET
H1 2026 Interim Results Presentation August 20, 2026 ASX: TLX | NASDAQ: TLX Radiopharmaceutical manufacturing suite at TMS North Melbourne.
EX-99.1 to Form 6-K
Aug 19, 2026, 9:48 PM ET
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Aug 19, 2026, 9:48 PM ET
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Jul 21, 2026, 7:06 AM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Jul 2, 2026, 4:27 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
May 21, 2026, 4:10 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
May 21, 2026, 4:10 PM ET
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
May 21, 2026, 4:10 PM ET
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Apr 22, 2026, 7:49 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Apr 21, 2026, 4:05 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Apr 20, 2026, 4:28 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Apr 14, 2026, 9:30 AM ET
Melbourne (Australia) and Indianapolis, IN (U.S.) – April 14, 2026 . Telix
EX-99.1 to Form 6-K
Apr 14, 2026, 6:02 AM ET
Melbourne (Australia) and Indianapolis, IN (U.S.) – April 14, 2026 . Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“ Telix ”)
EX-99.1 to Form 6-K
Apr 14, 2026, 6:02 AM ET
Post- treatment Pre- treatment Investor presentation April 14, 2026 ASX: TLX | NASDAQ: TLX 18F-FET scan published in EJNMMI
EX-99.2 to Form 6-K
Apr 13, 2026, 4:01 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Apr 9, 2026, 9:26 PM ET
REPORT OF FOREIGN PRIVATE ISSUER
EX-99.1 to Form 6-K
Apr 8, 2026, 9:23 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Apr 7, 2026, 6:27 AM ET
1 Telix media release March 9, 2026. ClinicalTrials.gov ID: NCT06520345.
EX-99.1 to Form 6-K
Apr 2, 2026, 4:03 PM ET
is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
EX-99.1 to Form 6-K
Mar 16, 2026, 5:00 PM ET
LAT2 7 . This enables TLX101-Px to be potentially utilized as a companion diagnostic agent to TLX101-Tx (iodofalan 131 I), Telix’s LAT1-targeting glioblastoma (GBM) therapy candidate, currently under investigation in the pivotal IPAX-BrIGHT study 8 .
EX-99.1 to Form 6-K
Mar 10, 2026, 4:57 PM ET
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
EX-99.1 to Form 6-K
Mar 10, 2026, 4:57 PM ET
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Feb 19, 2026, 5:22 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Feb 19, 2026, 5:22 PM ET
Depository Registry JP Morgan Chase Bank N.A. Shareowner Services P.O. Box 64504 St. Paul, MN 55164-0854 General (within US) +1 800 990 1135 From outside the US +1 651 453 2128 www.shareowneronline.com 20
EX-99.2 to Form 6-K
Feb 19, 2026, 5:22 PM ET
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Feb 18, 2026, 9:12 AM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Feb 2, 2026, 8:50 PM ET
Chair Resignation, Dr. Mark Nelson appointed Interim Chair
EX-99.1 to Form 6-K
Jan 20, 2026, 4:15 PM ET
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
EX-99.1 to Form 6-K
Jan 20, 2026, 4:15 PM ET
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Jan 12, 2026, 4:07 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Dec 22, 2025, 6:52 AM ET
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
EX-99.1 to Form 6-K
Dec 17, 2025, 4:06 PM ET
Additional information on the Phase 3 ProstACT Global study can be found at:
EX-99.1 to Form 6-K
Dec 8, 2025, 4:08 PM ET
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
EX-99.1 to Form 6-K
Oct 14, 2025, 8:36 AM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Telix Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TLX.

Revenue growth55.6% · median 6.6%

Gross margin53.1% · median 50.6%

Operating margin3.7% · median -39.8%

Net margin-0.9% · median -32.1%

Company	Revenue	Growth
ANIP	$978.38M	+30.9%
TLX	$803.79M	+55.6%
RARE	$717.21M	+17.5%
OPK	$587.90M	-11.5%
HCM	$204.89M	-4.3%
AAPG	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 1,120
Auditor: PricewaterhouseCoopers
SEC CIK: 2007191

Advertisement
300 × 250